Drugs / SY-4835
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05291182 | Jun 2021 → Jun 2024 | neoplasm | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-4835 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05291182 ↗ |
| Route | Oral | “SY-4835 administered orally” NCT05291182 ↗ |